Evidence map›Paper›PMID 32899528›Full record

ArticleDiagnostics (Basel, Switzerland)2020

Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable.

Radek Lakomy, Tomas Kazda, Iveta Selingerova, Alexandr Poprach, Petr Pospisil, Renata Belanova, Pavel Fadrus, Martin Smrcka, Vaclav Vybihal, Radim Jancalek and 7 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. BMC cancer · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Radek LakomyDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.ORCID 0000-0003-4961-0339
Tomas KazdaDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.ORCID 0000-0001-7288-8975
Iveta SelingerovaResearch Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Alexandr PoprachDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Petr PospisilDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Renata BelanovaDepartment of Radiology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Pavel FadrusDepartment of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Martin SmrckaDepartment of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Vaclav VybihalDepartment of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Radim JancalekDepartment of Neurosurgery, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic.
Igor KissDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Katarina MuckovaDepartment of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Michal HendrychFirst Department of Pathology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, 656 91 Brno, Czech Republic.
Andrea KnightDepartment of Pathological Physiology, Faculty of Medicine, Gamma Delta T Cell Laboratory, Masaryk University, 625 00 Brno, Czech Republic.
Jiri SanaDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Pavel SlampaDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Ondrej SlabyCentral European Institute of Technology, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
Masaryk University · CZCentral European Institute of Technology · CZMasaryk Memorial Cancer Institute · CZ

Funding

Ministerstvo Zdravotnictví Ceské Republiky MMCI, 00209805 and FNBr, 65269705, NU20-03-00148 and NV19-05-00410
6 · The paper itself

Abstract

backgroundThe aim of this retrospective study is to assess the incidence, localization, and potential predictors of rapid early progression (REP) prior to initiation of radiotherapy in newly diagnosed glioblastoma patients and to compare survival outcomes in cohorts with or without REP in relation to the treatment.

methodsWe assessed a consecutive cohort of 155 patients with histologically confirmed irradiated glioblastoma from 1/2014 to 12/2017. A total of 90 patients with preoperative, postoperative, and planning MRI were analyzed.

resultsMedian age 59 years, 59% men, and 39 patients (43%) underwent gross total tumor resection. The Stupp regimen was indicated to 64 patients (71%); 26 patients (29%) underwent radiotherapy alone. REP on planning MRI performed shortly prior to radiotherapy was found in 46 (51%) patients, most often within the surgical cavity wall, and the main predictor for REP was non-radical surgery (p < 0.001). The presence of REP was confirmed as a strong negative prognostic factor; median overall survival (OS) in patients with REP was 10.7 vs. 18.7 months and 2-year survival was 15.6% vs. 37.7% (hazard ratio HR 0.53 for those without REP;

conclusionEspecially in the subgroup of patients without radical resection, one may recommend as early initiation of radiotherapy as possible. The phenomenon of REP should be recognized as an integral part of stratification factors in future prospective clinical trials enrolling patients before initiation of radiotherapy.

Indexed as

chemotherapyglioblastomaoverall survivalradiotherapyrapid early progression

Identifiers

PMID32899528
PMCPMC7555958
OpenAlexW3083421441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.